Refractory, primary Central Nervous System Neoplasm Completed Phase 1 Trials for Entinostat (DB11841)
Also known as: Refractory Primary Central Nervous System Neoplasm
| Indication | Status | Phase |
|---|---|---|
| DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm) | Completed | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02780804 | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Treatment |